ArticleCase reports in dermatology
Multiple Bowen's Disease in a Patient Treated with Ruxolitinib: A Case Report and Extended Review of the Literature.
Article in Case reports in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor approved for the treatment of myelofibrosis and polycythemia vera, has been associated with an increased risk of non-melanoma skin cancer. While squamous cell carcinoma (SCC), basal cell carcinoma, and keratoacanthomas are commonly reported, Bowen's disease (BD), the in situ form of SCC, has been only rarely described. Case Presentation: We report the case of a 53-year-old woman with polycythemia vera, treated with ruxolitinib for over 9 years. Six months after a dose escalation, she developed multiple erythematous, hyperkeratotic plaques on the trunk and limbs. Histopathological examination confirmed the diagnosis of BD. Over the years, she continued to develop new lesions approximately once per year. All lesions were managed successfully with cryotherapy or surgical excision, and no invasive SCC was observed. She has been under close dermatologic surveillance with full-body skin examinations every 6 months. Conclusion: This is the first fully documented case of eruptive, multiple BD associated with long-term ruxolitinib therapy. The distinctive chronic pattern, histologically confirmed and followed prospectively for nearly a decade, highlights a potentially underrecognized cutaneous adverse effect of JAK inhibition, warranting further research and awareness among prescribing clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.